Inmune Bio, Inc.
Clinical trials sponsored by Inmune Bio, Inc., explained in plain language.
Clinical-stage biopharmaceutical company developing immunotherapies for cancer and inflammation.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Experimental drug INB03 tested to stop COVID-19 lung decline – trial halted early
Disease control Stopped earlyThis study tested a drug called INB03 in 79 high-risk COVID-19 patients to see if it could prevent their breathing from getting worse. Participants received two weekly injections of either INB03 or a placebo. The trial was terminated early, so we do not have clear results on whet…
Phase 2/3 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental INKmune therapy for blood cancers halted after just 2 patients
Disease control Stopped earlyThis early-stage study tested an experimental drug called INKmune in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to find a safe dose and check for side effects. However, the study was stopped early after only 2 people enrolled, so no c…
Phase 1 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Alzheimer's drug extension trial halted early — what we know
Disease control Stopped earlyThis study gave Alzheimer's patients who had already completed earlier XPro1595 trials an extra 55 to 74 weeks of the drug to check long-term safety and effects on memory and brain health. Only 11 people took part, and the trial was terminated early, so the findings are limited. …
Phase 2 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC